Devyn joined Therna Biosciences Board of Directors as an independent member in 2026. He has served as Chief Executive Officer and a member of the Board of Arbor since April 2021. He is a longtime board member and former Chairman of the Alliance for Regenerative Medicine (ARM) and advises and serves on the boards of multiple biotechnology companies.

Previously, Devyn was Chief Operating Officer and Head of Strategy at Sigilon Therapeutics and held senior strategy and operations roles at Pfizer Research and Development in both the U.S. and U.K., including leadership positions supporting regenerative medicine and neuroscience programs. Earlier in his career, Devyn worked in management consulting, advising pharmaceutical and biotechnology companies across a range of therapeutic areas and technologies, with a strong focus on regenerative medicine.

Devyn holds a Ph.D. in Genetics from Harvard Medical School, where his research resulted in multiple publications in leading scientific journals. He also holds an M.S. in Biology and a B.S. in Zoology and is currently an adjunct faculty member at Northeastern University.